NEW YORK, April 4, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Yadin Rozov to its Board of Directors effective April 1, 2022. The Board determined that Mr. Rozov qualifies as an independent director under the listing rules of the Nasdaq Capital Market.
Mr. Rozov is an investment professional with over twenty years of experience in capital markets, corporate finance, investment banking, and investment management with substantial experience in corporate strategy and governance. He is the founder and Managing Partner of Terrace Edge Ventures LLC, a financial advisory firm. Previously, Mr. Rozov was a Partner of GoldenTree Asset Management LLC, a leading global credit asset management firm, where he also served as the Chief Executive Officer and President of Syncora Guarantee Inc. and Chief Executive Officer of Financial Guaranty UK Ltd, each of which are stand-alone specialty insurance companies owned by GoldenTree. Additionally, he was a Partner and Managing Director at Moelis & Company where he headed the Financial Institution Advisory group. While at Moelis, Mr. Rozov helped co-found College Avenue Student Loans LLC and served on its board and co-founded Chamonix Partners Capital Management LLC. Before Moelis, Mr. Rozov was a Managing Director at UBS AG, where he was the Head of the Americas for the Repositioning Group.
Mr. Rozov earned an M.Sc. in data science from Columbia University and a bachelor's degree with highest honors in physics and materials engineering from Rutgers University.
"We welcome Yadin as a new independent director. His deep experience in corporate finance will be an asset to Oramed as we advance toward becoming a commercial stage company following our pivotal Phase 3 studies for the world's first oral insulin capsule," said Oramed Chief Executive Officer, Nadav Kidron.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 trials and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).
For more information, please visit www.oramed.com
Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the potential of ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, historic results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed' s reports filed from time to time with the Securities and Exchange Commission.
SOURCE Oramed Pharmaceuticals Inc.